Tandem Diabetes Care designs and sells insulin pump systems for people with diabetes, led by the t:slim X2 pump. Its Control-IQ technology automates insulin delivery in a hybrid closed-loop setup that works with continuous glucose monitors. The company serves primarily Type 1 diabetes patients and clinicians seeking connected, app-linked pump therapy as an alternative to multiple daily injections.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 240.7 | — | -52.4 | — |
| Q3 2025 | 249.3 | — | -21.2 | — |
| Q4 2025 | 290.4 | — | -0.6 | — |
| Q1 2026 | 247.2 | — | -20.4 | — |
| Q2 2026 | 254.6 | 5.8% | -21.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: SL Science Holding Limited (SLBT), Bicara Therapeutics Inc. (BCAX), LB Pharmaceuticals Inc (LBRX), Safety Insurance Group, Inc. (SAFT), Healthcare Services Group, Inc. (HCSG), Kestra Medical Technologies, Ltd. (KMTS)